Stockreport

VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

Vascular Biogenics Ltd. - Ordinary Shares  (VBLT) 
Last vascular biogenics ltd. - ordinary shares earnings: 11/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: vblrx.com
PDF TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 [Read more]